Stocks · Health care · Biological Products, (No Diagnostic Substances)

CRISPR Therapeutics AG

CRSP Clue Score37

Switzerland Fiscal year ends December CIK 0001674416 Results filed 2 Nov 2026

Add to watchlist

What the insiders did Net selling

By person

25 insiders · 546 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Bradley J PhD Bolzon

Director

—

$121.48M (128)

−$121.48M

148,831

0.1539%

$7.41M

−97.9%

Rodger Novak

President

—

$72.16M (54)

−$72.16M

573,007

0.5926%

$28.52M

−52.8%

Samarth Kulkarni

Chief Executive Officer

—

$67.61M (109) scheduled

−$67.61M

311,899

0.3226%

$15.53M

+133.6%

Kurt Von Emster

Director

$1.50M (1)

$52.74M (46)

−$51.24M

1,164,268

1.20%

$57.96M

−55.3%

Simeon George

Director

$51.50M (3)

$720.37K (1) scheduled

+$50.78M

3,784,428

3.91%

$188.39M

+118.7%

Thomas Woiwode

Director

—

$27.77M (34)

−$27.77M

645,643

0.6677%

$32.14M

−83.8%

Lawrence Otto Klein

Cbo & COO

—

$26.01M (27) scheduled

−$26.01M

26,797

0.0277%

$1.33M

—

Celgene Corp /De/ entity

10% owner

—

$21.12M (21)

−$21.12M

4,173,019

4.32%

$207.73M

−21.0%

Aktiengesellschaft Bayer

10% owner

$12.00M (1)

—

+$12.00M

5,632,802

5.83%

$280.40M

+10.3%

James R. Kasinger

General Counsel and Secretary

—

$8.51M (22) scheduled

−$8.51M

95,857

0.0991%

$4.77M

+3,072%

Michael John Tomsicek

Chief Financial Officer

—

$5.61M (7) scheduled

−$5.61M

1,891

0.0020%

$94.13K

+361.2%

Raju Prasad

Chief Financial Officer

—

$5.60M (13) scheduled

−$5.60M

14,815

0.0153%

$737.49K

—

Versant Venture Capital IV, L.P. entity

10% owner

—

$5.17M (4)

−$5.17M

117,173

0.1212%

$5.83M

−96.1%

Tyler Dylan-Hyde

Chief Legal Officer

—

$5.01M (25) scheduled

−$5.01M

25,204

0.0261%

$1.25M

−87.7%

Tony W Ho

Executive VP, Head of R&D

—

$4.52M (13) scheduled

−$4.52M

52,364

0.0542%

$2.61M

—

Vertex Pharmaceuticals (Europe) Ltd entity

10% owner

$3.19M (6)

—

+$3.19M

5,380,940

5.56%

$267.86M

+2.5%

Pablo J Cagnoni

Director

—

$1.73M (5) scheduled

−$1.73M

0

0.0000%

$0.00

—

Versant Venture Capital V, L.P. entity

10% owner

—

$1.16M (4)

−$1.16M

115,645

0.1196%

$5.76M

−16.5%

Douglas A Treco

Director

$1.14M (1)

—

+$1.14M

22,000

0.0228%

$1.10M

+1,000%

Ali Behbahani

Director

—

$780.94K (1) scheduled

−$780.94K

16,709

0.0173%

$831.77K

+38,758%

Naimish Patel

Chief Medical Officer

$49.70K (1)

$503.91K (3)

−$454.21K

19,357

0.0200%

$963.59K

+3,170%

Julianne Bruno

Chief Operating Officer

—

$336.10K (5)

−$336.10K

10,544

0.0109%

$524.88K

+238.9%

John Greene

Director

$313.95K (1)

—

+$313.95K

7,000

0.0072%

$348.46K

—

Brendan Smith

Chief Financial Officer

—

—

—

5,072

0.0052%

$252.48K

—

Phuong Khanh Morrow

Chief Medical Officer

—

—

—

4,411

0.0046%

$219.58K

—